



Review

Cite this article: Shen E, Shulha H, Weng Z, Akbarian S. 2014 Regulation of histone H3K4 methylation in brain development and disease. *Phil. Trans. R. Soc. B* **369**: 20130514. <http://dx.doi.org/10.1098/rstb.2013.0514>

One contribution of 19 to a Theme Issue 'Epigenetic information-processing mechanisms in the brain'.

Subject Areas:

bioinformatics, behaviour, molecular biology, neuroscience

Keywords:

chromatin, nucleosome, epigenetic, autism, schizophrenia, histone

Author for correspondence:

Schahram Akbarian
e-mail: schahram.akbarian@mssm.edu

Regulation of histone H3K4 methylation in brain development and disease

Erica Shen¹, Hennady Shulha², Zhiping Weng² and Schahram Akbarian¹

¹Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

²Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA 01604, USA

The growing list of mutations implicated in monogenic disorders of the developing brain includes at least seven genes (*ARX*, *CUL4B*, *KDM5A*, *KDM5C*, *KMT2A*, *KMT2C*, *KMT2D*) with loss-of-function mutations affecting proper regulation of histone H3 lysine 4 methylation, a chromatin mark which on a genome-wide scale is broadly associated with active gene expression, with its mono-, di- and trimethylated forms differentially enriched at promoter and enhancer and other regulatory sequences. In addition to these rare genetic syndromes, dysregulated H3K4 methylation could also play a role in the pathophysiology of some cases diagnosed with autism or schizophrenia, two conditions which on a genome-wide scale are associated with H3K4 methylation changes at hundreds of loci in a subject-specific manner. Importantly, the reported alterations for some of the diseased brain specimens included a widespread broadening of H3K4 methylation profiles at gene promoters, a process that could be regulated by the UpSET(KMT2E/MLL5)-histone deacetylase complex. Furthermore, preclinical studies identified maternal immune activation, parental care and monoaminergic drugs as environmental determinants for brain-specific H3K4 methylation. These novel insights into the epigenetic risk architectures of neurodevelopmental disease will be highly relevant for efforts aimed at improved prevention and treatment of autism and psychosis spectrum disorders.

1. Introduction

The 'epi- (greek for 'over', 'above') genome', with its rich cache of highly regulated, structural modifications—which include four different types of DNA methylcytosine derivatives and more than 100 different types of post-translational histone modifications and histone variants—defines the mouldings and three-dimensional structures of the genomic material inside the cell nucleus. Studies in human brain have indicated that the epigenetic landscape remains 'plastic' throughout all periods of brain development and ageing, with ongoing dynamic regulation occurring even in neurons and other postmitotic constituents of the brain [1–4]. Furthermore, mutations and structural variants in perhaps up to 50 genes, each encoding a different chromatin regulator, have been linked to a wide range of neurodevelopmental syndromes and rare, monogenic forms of autism and schizophrenia [5], and even adult-onset hereditary neurodegenerative disease [6–8]. Of note, on the list of mutations in chromatin-associated proteins linked to neurodevelopmental disease, some molecular systems stand out owing to a more prominent representation. These include, for example, at least seven members of the BAF family of molecules, which assemble into ATP-dependent chromatin remodelling complexes to regulate mobility of nucleosomes (the elementary units of chromatin, composed of 146 bp of DNA wrapped around an octamer of the core histones H2A/H2B/H3/H4) [5]. Here, we focus on methylation of the lysine (K) no. 4 residue of histone H3, a mark that on a genome-wide scale is broadly associated with transcriptional regulation and epigenetic tagging of promoter and enhancer sequences [9]. To date, mutations in five genes each encoding a H3K4-specific lysine methyltransferase or demethylase have been linked to developmental disability and impaired cognition, and several

additional disease-associated genes encode proteins with a key regulatory role for H3K4 methylation [5]. Furthermore, there is evidence that H3K4 methylation landscapes in the human cerebral cortex are dynamically regulated during prenatal development and throughout early childhood years until adolescence [10], and potentially altered in some cases on the autism [11] or schizophrenia spectrum [12]. Therefore, the findings from clinical genetics and the conclusions drawn from the epigenome mappings in brain tissue coalesce, and when taken together, leave little doubt that fine-tuning of H3K4 methylation is of fundamental importance during an extended period of human brain development.

2. H3K4 methylation: an overview

The functions of post-translational histone modifications (histone PTM) are highly specific in a site- and residue-specific manner, and include methylation, acetylation and crotonylation, polyADP-ribosylation and small protein (ubiquitin, SUMO) modification of specific lysine residues, as well as arginine (R) methylation and citrullination, serine (S) phosphorylation, tyrosine (T) hydroxylation, among others [13–15]. Methylation of the various lysine residues, including H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20, has been linked to transcriptional initiation and elongation, heterochromatic silencing and other chromatin functions [16]. The ammonium group of lysine side chains can carry up to three methyl groups, and for many of the aforementioned methyl-lysines, important differences in the distribution and regulation of the mono- (me1), di- (me2) and trimethylated (me3) forms emerged [16]. Powerful technologies, such as chromatin immunoprecipitation in conjunction with next-generation-sequencing-based quantification of the DNA (ChIP-seq), have been widely applied to various histone methylation markings in multiple tissues. In the case of H3K4, ChIP-seq studies have shown that the trimethylated form H3K4me3 is in human brain typically organized as approximately 30 000 sharp ‘peaks’ genome-wide [4,17]. These ‘peaks’, which often are cell-type specific and limited to 1–2 kb in length, are mostly found around transcription start sites (TSSs) of proximal gene promoters and other regulatory sequences, many of which are CpG enriched [18,19]. On a genome-wide scale, the H3K4me3 mark broadly correlates with RNA polymerase II occupancy at sites of active gene expression [20], and is thought to provide an additional layer of transcriptional regulation [21,22]. In striking contrast, the di- and mono-methylated forms, H3K4me2 and H3K4me1, are organized as much broader peaks when compared with H3K4me3 and tag a much larger proportion of open chromatin, including promoters and enhancers that positively regulate expression of genes which could be positioned many thousands of basepairs further down- or upstream [9,23]. When occurring together with sharp peaks of histone H3 acetylated at lysine 27 (H3K27ac), enrichment for H3K4me1 and/or H3K4me2 and in some cases, me3, is likely to flag active enhancer sequences [9,24]. Conversely, inactive enhancer sequences are defined by high levels of H3K4me1 but in the presence of the repressive mark, histone H3 trimethylated at lysine 27 (H3K27me3) [25] and at the expense of acetyl-H3K27 [24]. It has been proposed that some of the inactive enhancers tagged with the H3K4me1 mark is a reflection of their developmental potential, because

some of these sequences could be reset epigenetically into an active state under certain conditions, including differentiation, similar to the transiently occurring bivalent state of promoters dually tagged with open and repressive histone modifications in some stem cell types [24]. Interestingly, in brain chromatin, 70% of H3K4me1 sites are positioned *within* transcriptional units, which contrasts with many peripheral tissues that are defined by a somewhat higher representation of intergenic sequences at the expense of intragenic H3K4me1 [26]. The fact that brains show higher enrichments for H3K4me1 in intronic sequences in comparison with the peripheral tissues studied so far, could be explained by the fact that brain transcriptomes, in comparison with other tissues, show an overrepresentation of genes defined by high conservation of intronic sequence [26]. This finding could imply that transcriptional mechanisms in the brain rely more heavily on regulatory sequences within introns. In any case, proper H3K4 methylation is probably important to maintain open chromatin states in brain tissue. In this context, it is important to note that unmethylated H3K4 effectively serves as a DNA methylation signal which at promoters and enhancers is mostly associated with repression and inhibition of transcriptional activity [27,28].

3. H3K4-specific methyltransferases and demethylases

For a detailed review on lysine methyltransferases (KMTs) and demethylases (KDMs) as regulators of histone methylation, including the H3K4 residue, see Black *et al.* [29]. At least 11 genes in the human genome encode a protein with lysine methyltransferase activity specifically directed against the H3K4 residue. There are six H3K4-specific methyltransferases that share a highly conserved catalytic SET domain (*KMT2A-D*, *KMT2F-G*, which in the literature are better known under their older names *SET1A-B*, *MLL1–4*) [30] and additional genes (including *MLL5* (*KMT2E*), *ASH1* (*KMT2H*), *SMYD3* (*KMT3E*), *SET7/9* (*KMT7*), *MEIS2*); each of these proteins methylates H3K4 with high specificity [31]. The one exception is *MLL5* which is thought to harbour a SET domain that lacks catalytic activity [32,33]. The mixed-lineage leukaemia (MLL) group require additional subunits to attain maximal activity towards H3K4. A well-studied example would be the ‘WRAD’ (WDR5, RbBP5, ASH2L, DPY30) MLL-associated core complex [30,34]. Like the WRAD, the scaffolding protein MENIN has been shown to be important for MLL1-mediated H3K4me3/2/1 methylation [35–37]. Mechanistic studies *in vivo* are complicated by the frequent observation that dysregulation in one type of histone PTM causes secondary alterations in additional PTMs. For example, while MLL1 upregulates *in vitro* primarily mono- and di-methylated H3K4 [34], *Mill1* deficiency in some brain regions results not only in decreased H3K4me2 (as predicted from the *in vitro* data) but also lower levels of the trimethylated form (H3K4me3) around a subset of TSSs [12,38]. In addition, *Mill1* deficiency is associated with secondary effects on histone marks not directly regulated by the MLLs; for example, there is incomplete removal of a repressive histone mark, H3K27me3, at the H3K4me3-tagged promoters [39]. It is thought that the MLL1–4 enzymes each target a limited but very specific subset of genomic loci, including homeobox gene clusters as key regulators of morphogenesis and early

development [29]. Thus, MLL1 regulates less than 5% of promoters that carry an H3K4 trimethylation signal, whereas SET1A/B are thought to function as general regulators for this histone mark [37]. The (gene) target selectivity that defines some of the H3K4 KMTs could be due to differential binding to various cofactors and chromatin-associated proteins [40,41].

The H3K4-specific KMTs are complemented by an equally complex system of KDMs, with to date at least eight genes encoding a KDM that primarily (albeit often not exclusively) targets the H3K4 residue [29,31]. Active histone demethylation has been linked to two different mechanisms. The first type, represented by LSD1/KDM1A, involves an amine oxidase domain and flavin adenine dinucleotide (FAD) as cofactor to demethylate mono- and dimethylated lysines, including H3K4me2 and H3K4me1 [42], albeit activity against the H3K9 residue, particularly in complex with oestrogen or androgen receptors, also has been described [43–45]. Monoamine oxidase inhibitors (MAOi) such as tranylcypromine or phenelzine—powerful antidepressants that exert their therapeutic effects mainly by elevating brain monoamine levels through inhibition of MAO-A/B—also block LSD1-type histone demethylases [44]. The second type of demethylase, which in contrast to LSD1/LSD2 is capable of demethylating trimethyl markings, involves Fe²⁺-dependent dioxygenation by Jumonji-C (JmJC) domain-mediated catalysis [44]. The KDMs, like the KMTs, each show a specific combinatorial set of functional domains and (protein) binding partners [44,46], suggesting at least partial non-redundancy in function. For example, LSD1/KDM1A is thought to regulate histone methylation at promoters, whereas LSD2/KDM2B is bound to transcriptional elongation complexes and removes H3K4 methyl markings in gene bodies, thereby facilitating gene expression by reducing spurious transcriptional initiation outside of promoters [47].

4. Neurological disease associated with mutations in H3K4 regulators

Normal gene dosage of both for *MLL1* and *MLL4* is essential for human health, and haploinsufficiency of either gene is associated with developmental delay [48] and disability [49–51]. However, whether genetic ablation of each of these two orthologues results in overlapping behavioural, electrophysiological and molecular phenotypes remains an open question. Mutations in *MLL1* are thought to be responsible for the majority of cases with Wiedemann–Steiner syndrome (Mendelian inheritance in man (MIM) no. 605130), an extremely rare neurodevelopmental condition defined by intellectual disability, short stature, microcephaly and elbow hypertrichosis [51]. Furthermore, approximately 70% of patients with Kabuki syndrome (MIM no. 147920) carry deleterious mutations in *MLL4* [48]. Note that *MLL4* (a closer homologue to *MLL3*) in the literature is sometimes confused with *MLL2* (a close homologue to *MLL1*) [30]. We refer to *MLL4* (also known as *ALR*) as the KMT encoded on chromosome 12p13 that is mutated in Kabuki syndrome, and refer to *MLL2* (also known as *TRX2* or *Wbp7*) as the KMT encoded on chromosome 19q13. Kabuki syndrome, with more than 400 cases described worldwide, is defined by mild-to-moderate intellectual disability, failure to thrive in early childhood and short stature, and characteristic facial features, including elongated palpebral

fissures [48]. The MLLs, including *MLL1* and *MLL4*, are very large proteins 3972 (*MLL1*) and 5537 (*MLL4*) amino acids in length comprised 37 (*MLL1*) or 60 (*MLL4*) exons [30], with the majority of mutations thought to cause premature termination or frameshifts, and there is no apparent clustering of mutations around a specific functional domain [51]. The majority of mutations in Wiedemann–Steiner and Kabuki patients are likely to occur de novo, albeit a significant number of familial cases have been observed [51]. Additional cases with intellectual disability have been linked to single-point mutations in *MLL3* [52]. Strikingly, the list of monogenic neurodevelopmental disorders includes additional genes with an essential role for MLL-mediated H3K4 methylation. *CUL4B*, encoding a scaffold protein for the assembly of Cullin4B-ring ubiquitin ligase (CRL4B) complexes, is mutated in some cases with X-linked mental retardation (XLMR) [53–55]. Recently, it was discovered that *CUL4B* mediates ubiquitination and degradation of WDR5, a core subunit of the WRAD complex which is essential for MLL-mediated H3K4 methylation *in vivo* [56]. Consequently, downregulation of *CUL4B* resulted in elevated levels of WDR5 and H3K4 trimethylation on neuronal gene promoters [56].

Furthermore, missense mutations in the H3K4 demethylase *KDM5A/JARID1A* have been linked to an autosomal recessive form of intellectual disability [57] and, likewise, deleterious mutations in the X-linked *KDM5C/JARID1C/SMCX* could cause mental retardation and autism [58–60]. Furthermore, polyalanine (polyA)-tract-expansion-encoding mutations in the aristaless-related homeobox transcriptional regulator (*ARX*, MIM no. 300382), considered to rank among the most frequent causes of XLMR and epilepsy, are thought to lead to a dramatic downregulation of the *ARX*-driven transcription of *KDM5C* and, as a secondary effect, excessive H3K4 trimethylation [61]. To summarize then, at least seven genes—*MLL1*, *MLL2*, *MLL3*, *KDM5A*, *KDM5C*, *ARX*, *CUL4B*—each ascribed an essential role in the regulation of H3K4 methylation, are linked to rare monogenic forms of neurodevelopmental disease, including intellectual disability and autism (figure 1 and table 1).

5. Mouse models for genetic disorders associated with H3K4 methylation defects

The aforementioned subjects diagnosed with Wiedemann–Steiner or Kabuki syndrome are haploinsufficient for *MLL1* or *MLL4*. Interestingly, like their human counterparts, brain function is abnormal in *Mill* mutant mice that carry only one intact copy of the gene. These *Mill*^{+/−} heterozygous mice are affected by robust deficits in hippocampal learning and memory [79] and synaptic plasticity [80], whereas conditional deletion of both *Mill* alleles in stem cells residing in the subventricular zone results in severe defects in neurogenesis, whereas the glial lineage remains relatively unaffected [39]. Homozygous *Mill* null mutant mice die during early embryogenesis (around E10) but, interestingly, deletion of the catalytic SET domain alone is not lethal [81]. It is not known whether selective ablation of the SET domain would result in a brain phenotype in mice. Furthermore, conditional deletion of *Mill2* (the closest homologue to *Mill1* among all other Mlls and SET-domain containing H3K4 KMTs) also causes a deficit in hippocampus-dependent memory functions in mice [82], which would suggest that *Mill1* and *Mill2* are non-redundant




Figure 1. Molecular mechanisms of the seven genes (ARX, CUL4B, KDM5A, KDM5C, KMT2A, KMT2C, KMT2D) that play an essential role in H3K4 methylation and for which loss-of-function mutations are implicated in monogenic disorders of the developing brain. ARX is a homeodomain transcription factor; CUL4B is a ubiquitin ligase; KDM5A and KDM5C are H3K4 demethylases; KMT2A, KMT2C and KMT2D are H3K4-specific methyl transferases. ARX is a key transcriptional regulator for KDM5C, and CUL4B plays a role in the degradation of WDR5, a key component of the WRAD (MLL cofactor) complex. See text for further details. (Online version in colour.)

in function. There is no information yet whether deficiency in *Mll4* (the gene mutated in Kabuki syndrome) would result in abnormal brain function and behaviours. The molecular defects in the aforementioned *Mll* mutant mouse generally are in good agreement with current concepts on MLL function, including selective effects on a small subset of neuronal or glial transcripts, in the absence of global shifts in neuronal or glial transcriptomes. For example, conditional *Mll2* deletion in hippocampal neurons affected transcript levels for as little as 22 genes in the CA pyramidal neurons, and 161 genes in the dentate gyrus, together with corresponding changes in H3K4me2 and H3K4me3 that were confined to promoters of only the genes that were subjected to altered expression [82].

To the best of our knowledge, there are no studies exploring behavioural alterations in H3K4-specific KDMs, including *Kdm5a* and *Kdm5c*. However, it has been reported that RNA-induced *Kdm5c* knockdown in rat cerebellar granule neurons reduces dendritic length, and furthermore, *Kdm5c* is essential for neuronal survival during zebrafish development [59]. Interestingly, in cultured *Arx* null mutant cells, *Kdm5c* levels are severely reduced in differentiating GABAergic neurons [61]. Furthermore, conditional *Arx* deletion in the ganglionic eminence which contributes the largest proportion of interneurons for the cerebral cortex, leads to seizure disorders and neurocognitive deficits in mice [83].

6. Disordered H3K4 methylation in brain of subjects diagnosed with autism and schizophrenia, and in the animal model

As discussed above, multiple monogenic forms of neurodevelopmental disease have been linked to dysregulated H3K4

methylation. It is very likely that proper regulation and fine-tuning of the H3K4-methyl marks is pivotal for healthy brain development, because both mutations associated with loss (*MLL1*, *MLL4*) and gain of H3K4 methylation (*ARX*, *CUL4B*, *KDM5A*, *KDM5C*) potentially result in intellectual disability and autism, microcephaly, seizure disorder and other neurological disease in early childhood. Furthermore, there is increasing evidence that H3K4 methylation landscapes undergo genome-wide reorganization during early development. For example, in the human cerebral cortex, neuronal and glial H3K4-trimethyl profiles are subjected to significant remodelling at the site of 1000–1500 genes during the transitions from the late gestational period to early and late childhood [10]. Such developmentally programmed remodelling of neuronal and glial H3K4 methylation marks most certainly overlaps with the time period for vulnerability of common psychiatric disorders with a neurodevelopmental aetiology, including autism and schizophrenia. Autism spectrum disorders (ASD) are a group of conditions bound together by broad syndromic overlap of three key behavioural deficits in social interaction, communication and restricted, stereotypical or repetitive behaviour. ASDs also present with intellectual disability and neurological manifestations, including seizure disorder, and other movement disorders. The age of onset of ASD falls within early childhood, mostly within the first 36 months after birth. It is currently estimated that one of every 88 children born in the USA will be diagnosed with ASD [84]. Schizophrenia is a disorder affecting approximately 1% of the general population. Its core symptoms include defects of motivation, thought and cognition, and delusions and hallucinations [85]. The disease typically becomes manifest during young-adult years, but shows, in terms of genetic [86,87] and neurodevelopmental risk architectures [88,89], substantial overlap with ASD and related psychiatric disorders.

Table 1. List of monogenic neurodevelopmental diseases associated with the seven essential regulators of H3K4 methylation.

function	gene	MIM ID	predicated alteration of H3K4 methylation owing to mutations or genetic variations	associated phenotype and MIM number	references
lysine(K)-methyl transferases (KMTs)	KMT2A/MII1	159555	decreased	Wiedemann–Steiner syndrome (605130); microcephaly; autism; aggression	[51]
	KMT2C/MII3	606833	decreased	Kleefstra syndrome (610253); autism; microcephaly; intellectual disability; seizures; aphasia; anxiety; depression	[52,62,63]
	KMT2D/MII4 ('MII2')	602113	decreased	Kabuki syndrome 1 (147920); autism; seizures; microcephaly; cortical atrophy without hydrocephaly	[48–50,64,65]
lysine(K)-specific demethylase (KDMs)	KDM5A/JARID1A	180202	increased	intellectual disability	[57]
	KDM5C/SMCX	314690	increased	Claes-Jensen type X-linked mental retardation (300534); microcephaly; seizures	[57,66,67]
homeodomain transcription factor	ARX	300382	increased	early infantile epileptic encephalopathy-1 (308350); hydranencephaly with abnormal genitalia (300215); X-linked lissencephaly (300215); X-linked mental retardation (300419); Partington syndrome (309510); Proud syndrome (300004); intellectual disability; seizures	[68–74]
ubiquitin ligase	CUL4B	300304	increased	Cabezas type X-linked mental retardation (300354); macrocephaly; intellectual disability; seizures	[53,55,75–78]

Therefore, given that multiple regulators of H3K4 methylation are associated with neurodevelopmental disease, and given that the H3K4 methylation is subject to dynamic changes during the extended period of development and maturation of the human brain, it remains possible that this epigenetic mark is more broadly involved in the pathophysiology of the aforementioned common psychiatric conditions. While it is unlikely that mutations or genetic variations in H3K4-specific KMTs and KDMs, or their regulatory networks, play a role outside of affecting a very small subset of subjects diagnosed with autism, schizophrenia and other common psychiatric disease such as depression, dysregulated H3K4 methylation could play an important role in the pathophysiology, by providing a molecular bridge that links the internal and external environment of the neuronal and glial genomes in the brain. As illustrated by the following findings from independent animal models of relevance for the neurobiology of autism and psychosis spectrum disorders, there can be little doubt that H3K4 methylation landscapes of brain cells are sensitive

to a wide range of environmental perturbations. First, the H3K4me3 mark undergoes both global and gene-specific alterations in hippocampus of fear-conditioned animals [79]. Second, different levels of maternal care are associated with changes in H3K4me3 at the metabotropic glutamate receptor gene (*mGluR1*) in hippocampus of adult offspring [90]. Third, studies in mice have shown that activation of the maternal immune system by the cytokine activator and viral RNA mimic polyriboinosinic–polyribocytidilic acid (poly IC), which leads to behavioural deficits in the adult offspring reminiscent of autism and schizophrenia [91,92], could result in robust but transient changes in H3K4 methylation at cytokine signalling and other genes in the fetal brain, together with more subtle changes in adult offspring brain [93]. Fourth, prenatal exposure to the alkylating and antimitotic agent methylazoxymethanol, such as the aforementioned immune activation which is a popular paradigm to model the neurodevelopmental origins of psychosis [94], results in decreased H3K4 methylation in the adult prefrontal cortex




Figure 2. Broadening and ‘spreading’ of H3K4me3 peaks observed in some autism cases and the possible molecular explanation. (a) Clustered H3K4me3 profiles for entire Refseq transcription start sites (TSSs), within a -2 kilobase (kb) to $+2$ kb window around TSSs for prefrontal neurons from control and autism case no. 5. H3K4me3 signal intensity is illustrated using colour scaling with red representing a strong signal, white representing an intermediate signal and blue representing a weak signal. Note the extensive spreading of H3K4me3 profiles in the diseased case, compared with control. (b) Genome Browser tracks (from the University of California, Santa Cruz, CA) illustrate altered H3K4me3 profiles of the autism-susceptible gene *RAI1* in cortical neurons of autism cases no. 13 and 16 compared with the control subject. Note abnormally broad and flattened (‘spreaded’) peak shape in case no. 13. (c) Hypothesized role of UpSET (MLL5) repressive chromatin complex to maintain normal promoter H3K4 methylation profiles. See text and Shulha *et al.* [11] for further details. (Online version in colour.)

[95]. Fifth, some drugs, including the atypical antipsychotic clozapine and the stimulant metamphetamine, alter H3K4 methylation signatures at specific gene promoters in cerebral cortex and striatum [12,96]. While there is no evidence to date that overall levels of H3K4 methylation are altered in brain tissue of subjects diagnosed with autism or schizophrenia [11,97], changes at specific loci have been reported. In a recent genome-wide study, H3K4me3 was quantified in neuronal chromatin from the prefrontal cortex of 16 subjects on the autism spectrum [11]. Remarkably, not a single locus reached statistical significance on the cohort level. However, more than 700 sequences genome-wide showed a significant methylation change in at least one of the autism brains, in comparison with each of the controls, without exception. Interestingly, there was a two- to threefold, significant enrichment for genes and loci conferring genetic risk for neurodevelopmental disease. Furthermore, for many loci with an abnormal epigenetic signal in one (or several) autistic individuals, changes in gene expression could be documented for at least some of the very same cases with altered histone methylation. Based on these findings [11], one could conclude that each of the diseased brains showed a subject-specific H3K4 methylation signature, with each individual affected by a unique combinatorial set of abnormal histone methylation levels at select TSSs, together with altered expression of the associated gene transcripts. These individual-specific epigenetic alterations in the autism postmortem cohort included *AUTS2*, *PARK2*, *RIA1*, *RIMS3*, *SHANK3*, *VGEL* and many other susceptibility loci with high penetrance for disease risk. This finding suggests that in autism, epigenetic and genetic risk maps overlap significantly. Whether the observed H3K4 methylation changes are linked to a DNA sequence alteration

in *cis* or elsewhere in the genome (*trans*); reflect an adaptive or maladaptive response to environmental effects; are the outcome of some secondary or tertiary process in the neurobiology of disease; or are simply an epiphenomenon, remains to be determined in future studies.

One interesting finding that emerged from the genome-wide, next-generation-sequencing-based mapping of H3K4me3 in prefrontal neurons of subjects with autism spectrum was the ‘spreading’ of this histone mark away from the TSSs and encroaching into gene bodies and upstream sequences [11] (figure 2a,b). This alteration, which affected 4/16 cases but none of the controls, resulted in a significant broadening of the neuronal H3K4me3 peaks [11], which in normal brain are overwhelmingly organized into sharp peaks extending over 1–2 kb or less [4]. Interestingly, UpSET, the MLL5 homologue of *Drosophila*, assembles with Rpd/Sin3-repressor complexes and thereby regulates promoter-associated histone acetylation and H3K4 tri- and di-methylation. Strikingly, loss or decrease of UpSET alters chromatin architectures of promoters, including broadening of H3K4me3 peaks [32]. Whether or not MLL5 plays a role in the observed H3K4me3 peak broadening that affects neuronal chromatin of some subjects with autism [11] will await further investigations (figure 2c). In either case, these findings serve as important reminders that epigenetic alterations in neuropsychiatric disease should not solely be viewed in quantitative terms as ‘increase’ or ‘decrease’, and should include shape, spread and spatial profiles of epigenetic markings at specific sequences.

In addition to the aforementioned work in autism brains, genome-wide histone methylation surveys have been conducted in schizophrenia. One study explored H3K4me3 changes in cultured cells, including immature neurons, which were derived

from a biopsy of the olfactory epithelium of four subjects with schizophrenia and four matched controls [98]. Again, hundreds of loci showed H3K4 methylation changes in the disease cases, and at least 72 genes, some of which were of relevance for oxidative stress, metabolism and cellular (incl. synaptic) signalling, were affected by altered H3K4me3 in conjunction with altered expression. In addition to these genome-wide surveys, a number of studies reported changes in H3K4 methylation at neuronal signalling genes in brains of subjects diagnosed with schizophrenia or depression [12,99,100].

7. Outlook

As discussed above, multiple genes encoding regulators of H3K4 methylation are linked to monogenic forms of neurodevelopmental disease, thus accounting for some of the strongest genetic risk factors for intellectual disability and ASD. Changes in H3K4me1/2/3 have also been observed at numerous loci in cerebral cortex of subjects diagnosed with autism, schizophrenia and even depression, though it should be noted that these studies cannot clarify whether the observed H3K4 methylation changes were upstream of the disease process as opposed to a secondary effect, or epiphenomenon of the disease process. Interestingly, in the animal model, H3K4 methylation markings are sensitive to drugs interfering with dopamine and other monoamine signalling, and to various environmental perturbations. Thus, the question arises whether regulators of H3K4 methylation could emerge as promising drug targets for the treatment of brain disorders. To the best of our knowledge, preclinical or clinical studies targeting regulators of

H3K4 methylation for drug-based treatment of neurological or psychiatric disease have not yet been reported. Given that other types of 'epigenetic' drug treatments, including histone deacetylase inhibitors, exhibit a surprisingly broad therapeutic profile in the preclinical model, including depression and other psychiatric illnesses [101–103] in addition to various neurological disorders [8], it will be extremely interesting to target H3K4 methylation in the treatment of neurodevelopmental and neuropsychiatric disease. Furthermore, the rationale for such an approach is provided by recent studies reporting that RNA-mediated knockdown of H3K4-specific methyltransferases and demethylases, including Mll1 and Kdm5c, affects reward- and addiction-related behaviours in the adult animal [96]. Finally, while the focus of this review was on H3K4 methylation and neurodevelopment, it should be mentioned that regulatory mechanisms associated with several additional types of histone methylation, including H3K9, H3K27 and other repressive marks, have also been implicated in various disorders of the developing and adult brain [31,104–106].

Note added in proof

While this paper was in print, Takata *et al.* [107] reported that loss-of-function variants of the H3K4-specific methyltransferase SETD1 (SET domain-containing 1A/SET1A) are associated with genetic susceptibility for schizophrenia.

Funding statement. Work in the authors' laboratory is supported by grants from the National Institutes of Health and the Brain Behavior Research Foundation.

References

- Numata S *et al.* 2012 DNA methylation signatures in development and aging of the human prefrontal cortex. *Am. J. Hum. Genet.* **90**, 260–272. (doi:10.1016/j.ajhg.2011.12.020)
- Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiwicz D, Jaenisch R, Laird PW, Akbarian S. 2007 DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. *PLoS ONE* **2**, e895. (doi:10.1371/journal.pone.0000895)
- Hernandez DG *et al.* 2011 Distinct DNA methylation changes highly correlated with chronological age in the human brain. *Hum. Mol. Genet.* **20**, 1164–1172. (doi:10.1093/hmg/ddq561)
- Cheung I, Shulha HP, Jiang Y, Matevosian A, Wang J, Weng Z, Akbarian S. 2010 Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. *Proc. Natl Acad. Sci. USA* **107**, 8824–8829. (doi:10.1073/pnas.1001702107)
- Ronan JL, Wu W, Crabtree GR. 2013 From neural development to cognition: unexpected roles for chromatin. *Nat. Rev. Genet.* **14**, 347–359. (doi:10.1038/nrg3413)
- Klein CJ *et al.* 2011 Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. *Nat. Genet.* **43**, 595–600. (doi:10.1038/ng.830)
- Winkelman J *et al.* 2012 Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. *Hum. Mol. Genet.* **21**, 2205–2210. (doi:10.1093/hmg/dd5035)
- Jakovcevski M, Akbarian S. 2012 Epigenetic mechanisms in neurological disease. *Nat. Med.* **18**, 1194–1204. (doi:10.1038/nm.2828)
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 2007 High-resolution profiling of histone methylations in the human genome. *Cell* **129**, 823–837. (doi:10.1016/j.cell.2007.05.009)
- Shulha HP, Cheung I, Guo Y, Akbarian S, Weng Z. 2013 Coordinated cell type-specific epigenetic remodeling in prefrontal cortex begins before birth and continues into early adulthood. *PLoS Genet.* **9**, e1003433. (doi:10.1371/journal.pgen.1003433)
- Shulha HP *et al.* 2012 Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. *Arch. Gen. Psychiatry* **69**, 314–324. (doi:10.1001/archgenpsychiatry.2011.151)
- Huang HS, Matevosian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S. 2007 Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. *J. Neurosci.* **27**, 11 254–11 262. (doi:10.1523/JNEUROSCI.3272-07.2007)
- Kouzarides T. 2007 Chromatin modifications and their function. *Cell* **128**, 693–705. (doi:10.1016/j.cell.2007.02.005)
- Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. 2007 How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. *Nat. Struct. Mol. Biol.* **14**, 1025–40. (doi:10.1038/nsmb1338)
- Tan M *et al.* 2011 Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. *Cell* **146**, 1016–1028. (doi:10.1016/j.cell.2011.08.008)
- Zhou VW, Goren A, Bernstein BE. 2011 Charting histone modifications and the functional organization of mammalian genomes. *Nat. Rev. Genet.* **12**, 7–18. (doi:10.1038/nrg2905)
- Shulha HP *et al.* 2012 Human-specific histone methylation signatures at transcription start sites in prefrontal neurons. *PLoS Biol.* **10**, e1001427. (doi:10.1371/journal.pbio.1001427)
- Barrera LO, Li Z, Smith AD, Arden KC, Cavenee WK, Zhang MQ, Green RD, Ren B. 2008 Genome-wide mapping and analysis of active promoters in mouse

- embryonic stem cells and adult organs. *Genome Res.* **18**, 46–59. (doi:10.1101/gr.6654808)
19. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. 2007 A chromatin landmark and transcription initiation at most promoters in human cells. *Cell* **130**, 77–88. (doi:10.1016/j.cell.2007.05.042)
 20. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, Young RA. 2005 Global and Hox-specific roles for the MLL1 methyltransferase. *Proc. Natl Acad. Sci. USA* **102**, 8603–8608. (doi:10.1073/pnas.0503072102)
 21. Shilatifard A. 2008 Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. *Curr. Opin. Cell Biol.* **20**, 341–348. (doi:10.1016/j.ceb.2008.03.019)
 22. Shilatifard A. 2012 The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. *Annu. Rev. Biochem.* **81**, 65–95. (doi:10.1146/annurev-biochem-051710-134100)
 23. Maston GA, Landt SG, Snyder M, Green MR. 2012 Characterization of enhancer function from genome-wide analyses. *Annu. Rev. Genom. Hum. Genet.* **13**, 29–57. (doi:10.1146/annurev-genom-090711-163723)
 24. Creyghton MP *et al.* 2010 Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc. Natl Acad. Sci. USA* **107**, 21 931–21 936. (doi:10.1073/pnas.1016071107)
 25. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J. 2011 A unique chromatin signature uncovers early developmental enhancers in humans. *Nature* **470**, 279–283. (doi:10.1038/nature09692)
 26. Zhu J *et al.* 2013 Genome-wide chromatin state transitions associated with developmental and environmental cues. *Cell* **152**, 642–654. (doi:10.1016/j.cell.2012.12.033)
 27. Hu JL, Zhou BO, Zhang RR, Zhang KL, Zhou JQ, Xu GL. 2009 The N-terminus of histone H3 is required for de novo DNA methylation in chromatin. *Proc. Natl Acad. Sci. USA* **106**, 22 187–22 192. (doi:10.1073/pnas.0905767106)
 28. Ooi SK *et al.* 2007 DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* **448**, 714–717. (doi:10.1038/nature05987)
 29. Black JC, Van Rechem C, Whetstone JR. 2012 Histone lysine methylation dynamics: establishment, regulation, and biological impact. *Mol. Cell* **48**, 491–507. (doi:10.1016/j.molcel.2012.11.006)
 30. Ernst P, Vakoc CR. 2012 WRAD: enabler of the SET1-family of H3K4 methyltransferases. *Brief. Funct. Genomics* **11**, 217–226. (doi:10.1093/bfpg/els017)
 31. Peter CJ, Akbarian S. 2011 Balancing histone methylation activities in psychiatric disorders. *Trends Mol. Med.* **17**, 372–379. (doi:10.1016/j.molmed.2011.02.003)
 32. Rincon-Arango H, Halow J, Delrow JJ, Parkhurst SM, Groudine M. 2012 UpSET recruits HDAC complexes and restricts chromatin accessibility and acetylation at promoter regions. *Cell* **151**, 1214–1228. (doi:10.1016/j.cell.2012.11.009)
 33. Sebastian S, Sreenivas P, Sambasivan R, Cheedipudi S, Kandalla P, Pavlath GK, Dhawan J. 2009 MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation. *Proc. Natl Acad. Sci. USA* **106**, 4719–4724. (doi:10.1073/pnas.0807136106)
 34. Del Rizzo PA, Trievel RC. 2011 Substrate and product specificities of SET domain methyltransferases. *Epigenetics* **6**, 1059–1067. (doi:10.4161/epi.6.9.16069)
 35. Agarwal SK, Jothi R. 2012 Genome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors. *PLoS ONE* **7**, e37952. (doi:10.1371/journal.pone.0037952)
 36. Huang J, Gurusu B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X, Lei M. 2012 The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. *Nature* **482**, 542–546. (doi:10.1038/nature10806)
 37. Wang P *et al.* 2009 Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. *Mol. Cell. Biol.* **29**, 6074–6085. (doi:10.1128/MCB.00924-09)
 38. Katada S, Sassone-Corsi P. 2010 The histone methyltransferase MLL1 permits the oscillation of circadian gene expression. *Nat. Struct. Mol. Biol.* **17**, 1414–1421. (doi:10.1038/nsmb.1961)
 39. Lim DA, Huang YC, Swigut T, Mirick AL, Garcia-Verdugo JM, Wysocka J, Ernst P, Alvarez-Buylla A. 2009 Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. *Nature* **458**, 529–533. (doi:10.1038/nature07726)
 40. Wu M, Wang PF, Lee JS, Martin-Brown S, Florens L, Washburn M, Shilatifard A. 2008 Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS. *Mol. Cell. Biol.* **28**, 7337–7344. (doi:10.1128/MCB.00976-08)
 41. van Nuland R, Smits AH, Pallaki P, Jansen PW, Vermeulen M, Timmers HT. 2013 Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. *Mol. Cell. Biol.* **33**, 2067–2077. (doi:10.1128/MCB.01742-12)
 42. Ciccone DN, Su H, Hevi S, Gay F, Lei H, Bajko J, Xu G, Li E, Chen T. 2009 KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. *Nature* **461**, 415–418. (doi:10.1038/nature08315)
 43. Ruthenburg AJ, Allis CD, Wysocka J. 2007 Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. *Mol. Cell* **25**, 15–30. (doi:10.1016/j.molcel.2006.12.014)
 44. Mosammaparast N, Shi Y. 2010 Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. *Annu. Rev. Biochem.* **79**, 155–179. (doi:10.1146/annurev-biochem.78.070907.103946)
 45. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Günther T, Buettner R, Schüle R. 2005 LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. *Nature* **437**, 436–439.
 46. Selvi BR, Mohankrishna DV, Ostwal YB, Kundu TK. 2010 Small molecule modulators of histone acetylation and methylation: a disease perspective. *Biochim. Biophys. Acta* **1799**, 810–828. (doi:10.1016/j.bbaggm.2010.09.005)
 47. Fang R *et al.* 2010 Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. *Mol. Cell* **39**, 222–233. (doi:10.1016/j.molcel.2010.07.008)
 48. Hannibal MC *et al.* 2011 Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome. *Am. J. Med. Genet. A* **155**, 1511–1516. (doi:10.1002/ajmg.a.34074)
 49. Ng SB *et al.* 2010 Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. *Nat. Genet.* **42**, 790–793. (doi:10.1038/ng.646)
 50. Banka S *et al.* 2013 MLL2 mosaic mutations and intragenic deletion-duplications in patients with Kabuki syndrome. *Clin. Genet.* **83**, 467–471. (doi:10.1111/j.1399-0004.2012.01955.x)
 51. Jones WD *et al.* 2012 De novo mutations in MLL cause Wiedemann–Steiner syndrome. *Am. J. Hum. Genet.* **91**, 358–364. (doi:10.1016/j.ajhg.2012.06.008)
 52. Kleefstra T *et al.* 2012 Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. *Am. J. Hum. Genet.* **91**, 73–82. (doi:10.1016/j.ajhg.2012.05.003)
 53. Isidor B, Pichon O, Baron S, David A, Le Caignec C. 2010 Deletion of the CUL4B gene in a boy with mental retardation, minor facial anomalies, short stature, hypogonadism, and ataxia. *Am. J. Med. Genet. A* **152**, 175–180. (doi:10.1002/ajmg.a.33152)
 54. Badura-Stronka M, Jamsheer A, Materna-Kiryluk A, Sowinska A, Kiryluk K, Budny B, Latos-Bieleńska A. 2010 A novel nonsense mutation in CUL4B gene in three brothers with X-linked mental retardation syndrome. *Clin. Genet.* **77**, 141–144. (doi:10.1111/j.1399-0004.2009.01331.x)
 55. Tarpey PS *et al.* 2007 Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor. *Am. J. Hum. Genet.* **80**, 345–352. (doi:10.1086/511134)
 56. Nakagawa T, Xiong Y. 2011 X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression. *Molecular Cell* **43**, 381–391. (doi:10.1016/j.molcel.2011.05.033)
 57. Najmabadi H *et al.* 2011 Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* **478**, 57–63. (doi:10.1038/nature10423)
 58. Adegbolu A, Gao H, Sommer S, Browning M. 2008 A novel mutation in JARID1C/SMCX in a patient with autism spectrum disorder (ASD). *Am. J. Med. Genet. A* **146**, 505–511. (doi:10.1002/ajmg.a.32142)

59. Iwase S *et al.* 2007 The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. *Cell* **128**, 1077–1088. (doi:10.1016/j.cell.2007.02.017)
60. Abidi FE, Holloway L, Moore CA, Weaver DD, Simensen RJ, Stevenson RE, Rogers RC, Schwartz CE. 2008 Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia. *J. Med. Genet.* **45**, 787–793. (doi:10.1136/jmg.2008.058990)
61. Poeta L *et al.* 2013 A regulatory path associated with X-linked intellectual disability and epilepsy links KDM5C to the polyalanine expansions in ARX. *Am. J. Hum. Genet.* **92**, 114–125. (doi:10.1016/j.ajhg.2012.11.008)
62. Neale BM *et al.* 2012 Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* **485**, 242–245. (doi:10.1038/nature11011)
63. O’Roak BJ *et al.* 2012 Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* **485**, 246–250. (doi:10.1038/nature10989)
64. Banka S *et al.* 2012 How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. *Eur. J. Hum. Genet.* **20**, 381–388. (doi:10.1038/ejhg.2011.220)
65. Li Y *et al.* 2011 A mutation screen in patients with Kabuki syndrome. *Hum. Genet.* **130**, 715–724. (doi:10.1007/s00439-011-1004-y)
66. Jensen LR *et al.* 2005 Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. *Am. J. Hum. Genet.* **76**, 227–236. (doi:10.1086/427563)
67. Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F, Li J, Rao A, Shi Y. 2007 The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. *Nature* **447**, 601–605. (doi:10.1038/nature05823)
68. Bienvenu T *et al.* 2002 ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. *Hum. Mol. Genet.* **11**, 981–991. (doi:10.1093/hmg/11.8.981)
69. Grønskov K, Hjalgrim H, Nielsen IM, Brøndum-Nielsen K. 2004 Screening of the ARX gene in 682 retarded males. *Eur. J. Hum. Genet.* **12**, 701–705. (doi:10.1038/sj.ejhg.5201222)
70. Kato M *et al.* 2004 Mutations of ARX are associated with striking pleiotropy and consistent genotype–phenotype correlation. *Hum. Mutat.* **23**, 147–59. (doi:10.1002/humu.10310)
71. Kato M, Saitoh S, Kamei A, Shiraishi H, Ueda Y, Akasaka M, Hayasaka K. 2007 A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). *Am. J. Hum. Genet.* **81**, 361–366. (doi:10.1086/518903)
72. Kitamura K *et al.* 2002 Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. *Nat. Genet.* **32**, 359–369. (doi:10.1038/ng1009)
73. Proud VK, Levine C, Carpenter NJ. 1992 New X-linked syndrome with seizures, acquired micrencephaly, and agenesis of the corpus callosum. *Am. J. Med. Genet.* **43**, 458–466. (doi:10.1002/ajmg.1320430169)
74. Strømme P *et al.* 2002 Mutations in the human ortholog of Aristaless cause X linked mental retardation and epilepsy. *Nat. Genet.* **30**, 441–445. (doi:10.1038/ng862)
75. Cabezas DA, Slauch R, Abidi F, Arena JF, Stevenson RE, Schwartz CE, Lubs HA. 2000 A new X linked mental retardation (XLMR) syndrome with short stature, small testes, muscle wasting, and tremor localises to Xq24–q25. *J. Med. Genet.* **37**, 663–668. (doi:10.1136/jmg.37.9.663)
76. Ravn K, Lindquist SG, Nielsen K, Dahm TL, Tümer Z. 2012 Deletion of CUL4B leads to concordant phenotype in a monozygotic twin pair. *Clin. Genet.* **82**, 292–294. (doi:10.1111/j.1399-0004.2011.01839.x)
77. Tarpey PS *et al.* 2009 A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. *Nat. Genet.* **41**, 535–543. (doi:10.1038/ng.367)
78. Zou Y *et al.* 2007 Mutation in CUL4B, which encodes a member of cullin-RING ubiquitin ligase complex, causes X-linked mental retardation. *Am. J. Hum. Genet.* **80**, 561–566. (doi:10.1086/512489)
79. Gupta S, Kim SY, Artis S, Molfese DL, Schumacher A, Sweatt JD, Paylor RE, Lubin FD. 2010 Histone methylation regulates memory formation. *J. Neurosci.* **30**, 3589–3599. (doi:10.1523/JNEUROSCI.3732-09.2010)
80. Kim SY, Levenson JM, Korsmeyer S, Sweatt JD, Schumacher A. 2007 Developmental regulation of Eed complex composition governs a switch in global histone modification in brain. *J. Biol. Chem.* **282**, 9962–9972. (doi:10.1074/jbc.M608722200)
81. Ansari KI, Mandal SS. 2010 Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. *FEBS J.* **277**, 1790–1804. (doi:10.1111/j.1742-4658.2010.07606.x)
82. Kerimoglu C *et al.* 2013 Histone-methyltransferase MLL2 (KMT2B) is required for memory formation in mice. *J. Neurosci.* **33**, 3452–3464. (doi:10.1523/JNEUROSCI.3356-12.2013)
83. Marsh E *et al.* 2009 Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous females. *Brain* **132**, 1563–1576. (doi:10.1093/brain/awp107)
84. Christensen D *et al.* 2013 Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning: autism and Developmental Disabilities Monitoring Network, USA, 2008. *Dev. Med. Child Neurol.* **56**, 59–65. (doi:10.1111/dmcn.12268)
85. Ibrahim HM, Tamminga CA. 2010 Schizophrenia: treatment targets beyond monoamine systems. *Annu. Rev. Pharmacol. Toxicol.* **51**, 189–209. (doi:10.1146/annurev.pharmtox.010909.105851)
86. Kenny EM *et al.* 2013 Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders. *Mol. Psychiatry* epub ahead of print. (doi:10.1038/mp.2013.127)
87. Murdoch JD, State MW. 2013 Recent developments in the genetics of autism spectrum disorders. *Curr. Opin. Genet. Dev.* **23**, 310–315. (doi:10.1016/j.gde.2013.02.003)
88. Akbarian S, Huang HS. 2006 Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. *Brain Res. Rev.* **52**, 293–304. (doi:10.1016/j.brainresrev.2006.04.001)
89. Connor CM, Crawford BC, Akbarian S. 2011 White matter neuron alterations in schizophrenia and related disorders. *Int. J. Dev. Neurosci.* **29**, 325–334. (doi:10.1016/j.ijdevneu.2010.07.236)
90. Bagot RC, Zhang TY, Wen X, Nguyen TT, Nguyen HB, Diorio J, Wong TP, Meaney MJ. 2012 Variations in postnatal maternal care and the epigenetic regulation of metabotropic glutamate receptor 1 expression and hippocampal function in the rat. *Proc. Natl Acad. Sci. USA* **109**(Suppl. 2), 17 200–17 207. (doi:10.1073/pnas.1204599109)
91. Meyer U. 2013 Prenatal poly(I:C) exposure and other developmental immune activation models in rodent systems. *Biol. Psychiatry* **75**, 307–315. (doi:10.1016/j.biopsych.2013.07.011)
92. Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. 2013 Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. *Biol. Psychiatry* **75**, 332–341. (doi:10.1016/j.biopsych.2013.06.025)
93. Connor CM, Dincer A, Straubhaar J, Galler JR, Houston IB, Akbarian S. 2012 Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. *Schizophr. Res.* **140**, 175–184. (doi:10.1016/j.schres.2012.06.037)
94. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. 2006 A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. *Biol. Psychiatry* **60**, 253–264. (doi:10.1016/j.biopsych.2006.01.003)
95. Mackowiak M, Bator E, Latusz J, Mordalska P, Wedzony K. 2013 Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. *Eur. Neuropsychopharmacol.* **24**, 271–289. (doi:10.1016/j.euroneuro.2013.05.013)
96. Aguilar-Valles A, Vaissiere T, Griggs EM, Mikaelsson MA, Takacs IF, Young EJ, Rumbaugh G, Miller CA. 2013 Methamphetamine-associated memory is regulated by a writer and an eraser of permissive histone methylation. *Biol. Psychiatry* **76**, 57–65. (doi:10.1016/j.biopsych.2013.09.014)
97. Akbarian S *et al.* 2005 Chromatin alterations associated with down-regulated metabolic gene

- expression in the prefrontal cortex of subjects with schizophrenia. *Arch. Gen. Psychiatry* **62**, 829–840. (doi:10.1001/archpsyc.62.8.829)
98. Kano S *et al.* 2013 Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. *Mol. Psychiatry* **18**, 740–742. (doi:10.1038/mp.2012.120)
 99. Cruceanu C, Alda M, Nagy C, Freemantle E, Rouleau GA, Turecki G. 2013 H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depression. *Int. J. Neuropsychopharmacol.* **16**, 289–299. (doi:10.1017/S1461145712000363)
 100. Ernst C, Chen ES, Turecki G. 2009 Histone methylation and decreased expression of TrkB.T1 in orbital frontal cortex of suicide completers. *Mol. Psychiatry* **14**, 830–832. (doi:10.1038/mp.2009.35)
 101. Morris MJ, Karra AS, Monteggia LM. 2010 Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain. *Behav. Pharmacol.* **21**, 409–419. (doi:10.1097/FBP.0b013e32833c20c0)
 102. Covington 3rd HE *et al.* 2009 Antidepressant actions of histone deacetylase inhibitors. *J. Neurosci.* **29**, 11 451–11 460. (doi:10.1523/JNEUROSCI.1758-09.2009)
 103. Schroeder FA, Lin CL, Crusio WE, Akbarian S. 2007 Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. *Biol. Psychiatry* **62**, 55–64. (doi:10.1016/j.biopsych.2006.06.036)
 104. Parkel S, Lopez-Atalaya JP, Barco A. 2013 Histone H3 lysine methylation in cognition and intellectual disability disorders. *Learn. Mem.* **20**, 570–579. (doi:10.1101/lm.029363.112)
 105. Jarome TJ, Lubin FD. 2013 Histone lysine methylation: critical regulator of memory and behavior. *Rev. Neurosci.* **24**, 375–387. (doi:10.1515/revneuro-2013-0008)
 106. Gilman SR, Chang J, Xu B, Bawa TS, Gogos JA, Karayiorgou M, Vitkup D. 2012 Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. *Nat. Neurosci.* **15**, 1723–1728. (doi:10.1038/nn.3261)
 107. Takata A, Xu B, Ionita-Laza I, Roos JL, Gogos JA, Karayiorgou M. 2014 Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. *Neuron* **82**, 773–780. (doi:10.1016/j.neuron.2014.04.043)